Gyre Therapeutics Inc — Financial Statements (NASDAQ:GYRE)

Financials

Total revenue 20.9 M7.3 M0114.49 M107.3 M 107.61 M Gross profit 20.9 M7.3 M0108.81 M101.87 M 102.42 M Operating expenses 78.32 M95.23 M9.4 M176.04 M85.71 M 90.38 M Selling/general/admin expenses 16.18 M18.96 M17.37 M75.82 M73.62 M 77.79 M Research & development 52.98 M68.89 M13.04 M13.78 M12.02 M 12.6 M Operating income -57.37 M-87.89 M-8.61 M-67.23 M16.16 M 12.03 M Non-Operating Income, Total 659 K87 K0-1.52 M1.66 M 2.37 M Interest expense, net of interest capitalized ————9 000 — Non-Operating Income, excl. Interest Expenses 0174 K78 K03.31 M 3.53 M Unusual income/expense 659 K-87 K-78 K-1.52 M-1.66 M -1.16 M Pretax income 58.03 M87.98 M-7.89 M-76.97 M23.22 M 15.27 M Equity in earnings ————— — Taxes ——348 K8.52 M5.32 M 3.46 M Non-controlling/minority interest ———7.45 M5.81 M 5.16 M After tax other income/expense ————— — Net income before discontinued operations -56.24 M-87.93 M-8.24 M-85.48 M17.9 M 11.76 M Discontinued operations ————— — Net income -56.24 M-87.93 M-8.24 M-85.48 M17.9 M 11.76 M Dilution adjustment ————— — Preferred dividends ————— — Diluted net income available to common stockholders 56.24 M87.9 M8.2 M-92.93 M4.92 M 4.01 M Basic earnings per share (Basic EPS) ——-0.26-1.410.14 0.09 Diluted earnings per share (Diluted EPS) ——-0.26-1.410.05 0.05 Average basic shares outstanding ——31.55 M65.83 M85.09 M 347.52 M Diluted shares outstanding ——31.55 M65.83 M102.29 M 408.95 M EBITDA ———-65.11 M19.26 M 14.67 M EBIT ———-66.19 M17.71 M 12.38 M Cost of revenue ———4.64 M3.88 M 4.85 M Other cost of goods sold ————— — Depreciation & amortization (cash flow) 138 K290 K230 K1.07 M1.55 M 2.29 M